Depression Drugs Market (Drug Class: Selective Serotonin Reuptake Inhibitors [SSRIs], Serotonin and Norepinephrine Reuptake Inhibitors [SNRIs], Atypical Antidepressants, Tricyclic Antidepressants, and Others; Disease Type: Major Depressive Disorder, Schizophrenia and Bipolar I Disorder, Obsessive-Compulsive Disorders [OCD], Anxiety Disorder, and Others; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Entry of Novel Pharmacologic and Non-pharmacologic Interventions to Aid Market Growth

Depression today has emerged as a ‘silent killer’ in several regions around the world, particularly in urban cities. The prevalence of depression continues to grow at a rapid pace and has considerably high mortality and morbidity rate due to which, the healthcare sector continues its pursuit for novel medications and therapies. At present, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants among others. Although these drugs have proved to be highly effective, a large number of patients have reported side effects or have not responded to these drugs in the required manner.

However, advancements in the neurobiology of depression over the past few years have opened up new avenues for antidepressant treatment. In addition, in the current depression drugs market, market participants are increasingly focusing on the development of novel non-pharmacologic and pharmacologic interventions. Research and development activities are expected to continue in full swing during the course of the forecast period. In addition, several drug developers are increasingly pinning their hopes to establish a strong presence in the depression drugs market landscape on the FDA to approve their products.

At the back of these factors, along with growing awareness regarding depression, the global depression drugs market is expected to attain a market value of US$ 24.3 Bn by the end of 2030. The evolving regulatory landscape, along with the fast-paced development of new depression medications are likely to influence the overall growth trajectory of the depression drugs market during the assessment period.

Research and Development Activities to Remain Key for Market Growth

Major depressive disorder (MDD) continues to remain one of the leading causes of disability around the world. Conventional medications and methods to address depression have repeatedly exhibited a low success rate and are reportedly effective for ~40% patients. These factors have compelled researchers, scientists, and drug developers to explore new pathways that are likely to increase the efficacy of the treatment for major depressive disorder. Research and development activities are likely to influence the overall growth of the depression drugs market. Several research projects around the world are increasingly contributing to the development of novel medications, drugs, and therapies.

For instance, a team of researchers at the Icahn School of Medicine at Mount Sinai, are studying the interleukin-6 molecule– a protein that primarily facilitates communication between different cells. As per the research, individuals suffering from depression have higher levels of IL-6. Another aspect of the research primarily focuses on ezogabine– an anticonvulsant drug that offers immense promise in minimizing symptoms of depression, including low motivation, lack of interest, and inability to feel pressure, among others.

Get a glimpse of the in-depth analysis through our Report Brochure

To date, severe depression is largely treated with tricyclic anti-depressants– a class of drugs that is more effective than other classes of drugs used to address mild to moderate depression. However, the demand for tricyclic anti-depressants is gradually expected to decline due to the side effects associated with them. However, in March 2020, a group of researchers from the University of Copenhagen in collaboration with the National Institutes of Health in Baltimore and Lundbeck A/S has revealed that the team has discovered a potential drug that is likely to ease the side effects of medication that is used to address severe depression.

Market Participants Focus on Attaining FDA Approval for Newly Developed Drugs

Conventional classes of drugs, including monoamine oxidase inhibitors and tricyclic antidepressants have remained popular in the depression drugs market over the past three decades. Over time, the uptake of serotonin reuptake inhibitors, first-generation antipsychotics, and various modern forms of psychotherapy has increased at a rapid pace. Although several pharmaceutical companies have gradually refrained from investing resources in research activities due to continual failure of several trials, several market operators have pinned their hopes on ketamine and various other emerging psychiatric medications. The future of the mental health treatment sector primarily depends on two major factors– investments for drug development & clinical trials and approval from the FDA.

The FDA has played an integral role in introducing new drug therapies and medications to the depression drugs market in the U.S. For instance, in March 2019, the FDA approved a unique postpartum depression drugs that has offered promising results in clinical trials. Another major breakthrough in the depression drugs market is the approval of a nasal spray to address treatment-resistant depression. Similar such trends are expected to provide a notable boost to the overall growth of the depression drugs market during the assessment period.

Demand for Antidepressants Remains Steady amid COVID-19 Pandemic

The onset of the novel COVID-19 pandemic is expected to have an impact on the overall growth of the depression drugs market, as a large number of individuals suffering from mental health conditions is increasingly leaning toward prescription drugs such as benzodiazepines and antidepressants. In addition, as governments in several nations have imposed lockdowns as a preventive measure to contain the transmission of the novel coronavirus, the demand for antianxiety medications has witnessed a considerable growth. The number of prescriptions for antidepressants witnessed a noteworthy growth during the first two quarters of 2020 and the trend is likely to continue in the next two quarters of 2020.

Analysts’ Viewpoint

The global depression drugs market is expected to grow at a sluggish CAGR of 2.3% during the forecast period. Much of the market growth can be attributed to ongoing research and development activities, development of novel non-pharmacologic and pharmacologic interventions, increase in the number of collaborations between research institutes and pharmaceutical companies, and most importantly the growing prevalence of mild to severe depression around the world. Market players should focus on improving the effectiveness of their drugs, along with minimizing the side effects of the same.  

Depression Drugs Market: Overview

Depression drugs are medications used to treat major depressive disorders, some anxiety disorders, chronic pain conditions, and to help manage some addictions. Common side effects of depression drugs include dry mouth, weight gain, dizziness, headaches, and sexual dysfunction.

According to an analysis by the National Center for Health Statistics, the percentage of the U.S. population aged over 12 who took depression drugs was 12.7% in October 2017. Most depression drugs are used to treat depression, while some are prescribed for other conditions.

The burden of depression is rising across the world. According to the WHO, more than 800,000 people commit suicide every year, and depression is the second leading cause of death in people aged 15 to 29. Major depressive disorder (MDD) affects nearly 121 million people globally. According to the WHO, an estimated 4.4% of the global population suffers from depressive disorders and 3.6% from anxiety disorder. The World Health Survey (WHS) conducted in 2013 indicated that the prevalence of depression in countries classified according to economic development was similar, with 6.0% in low-income countries and 7.6% in upper-middle-income countries. Rise in the number of cases and increase in awareness among patients about diagnosis and treatment of depression are likely to drive the global depression drugs market.

Surge in Awareness about Depression

Rise in awareness about mental illness and available treatments drives the global depression drugs market. A number of people do not truly understand mental illness.

Remote counselling is increasing in the U.K., with services such as TalkSpace and BetterHelp pairing individuals with counsellors who can offer support and guidance over text messages. In Finland, an online therapy service called Mental Health Hub was set up 10 years ago in light of how hard it was for patients in rural areas to get help. Rise in awareness and technological advancements in communicating with people are expected to augment the depression drugs market in the near future.

Market Segmentation: Depression Drugs Market

In terms of drug class, the global depression drugs market has been divided into selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, tricyclic antidepressants, and others

Based on disease type, the global depression drugs market has been classified into major depressive disorder, schizophrenia and bipolar I disorder, obsessive-compulsive disorders (OCD), anxiety disorder, and others

In terms of distribution channel, the global depression drugs market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies

Each of the segments has been analyzed in detail for market trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The depression drugs market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment of the global depression drugs market from 2020 to 2030, along with market size estimations.

Regional Overview: Depression Drugs Market

In terms of region, the global depression drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.

The current and future market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the depression drugs market report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030

The study also offers a list of recommendations, highlights, and useful insights of the depression drugs market, which will help new companies willing to enter the market and existing companies to increase market share, and help in the decision-making process

Major Players

The report concludes with the company profiles section that includes key information about the major players in the depression drugs market

Leading players analyzed in the depression drugs market report are 

• Johnson & Johnson
• Otsuka Pharmaceutical Co., Ltd.,
• Allergan
• Novartis AG
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Abbott, Pfizer
• GlaxoSmithKline

Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Key Questions Answered in Depression Drugs Market Report

• What is the sales revenue expected to be generated by depression drugs across all regions during the forecast period?
• What are the opportunities in the global depression drugs market?
• What are the major drivers, restraints, opportunities, and threats in the global market?
• Which region is set to expand at the fastest CAGR during the forecast period?
• Which disease type segment is expected to generate the highest value globally in 2030? Which disease type segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Depression Drugs Market - Segmentation

Drug Class

• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
• Atypical Antidepressants
• Tricyclic Antidepressants
• Others (CNS Stimulants, Monoamine Oxidase Inhibitors, etc.)

Disease Type

• Major Depressive Disorder
• Schizophrenia and Bipolar I Disorder
• Obsessive-Compulsive Disorders (OCD)
• Anxiety Disorder
• Others (ADHD, SSRI-induced Disorder, etc.)

Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Depression Drugs Market 

4. Market Overview

    4.1.  Introduction & Overview

    4.2. Product Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities 

    4.4. Global Depression Drugs Market Analysis and Forecast, 2018–2030

5. Market Outlook 

    5.1. Pipeline Analysis 

    5.2. Disease Prevalence & Incidence Rate globally with key countries

    5.3. Regulatory Scenario 

    5.4. Key Mergers & Acquisitions

6. Global Depression Drugs Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Global Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        6.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        6.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        6.2.3. Atypical Antidepressants

        6.2.4. Tricyclic Antidepressants

        6.2.5.  Others

    6.3. Global Depression Drugs Market Attractiveness Analysis, by Drug Class

7. Global Depression Drugs Market Analysis and Forecast, by Disease Type

    7.1. Introduction & Definition

    7.2. Global Depression Drugs Market Value (US$) Forecast, by Disease Type, 2018–2030

        7.2.1. Major Depressive Disorder 

        7.2.2. Schizophrenia and Bipolar I Disorder 

        7.2.3. Obsessive-Compulsive Disorders (OCD)

        7.2.4. Anxiety Disorder

        7.2.5. Others

    7.3. Global Depression Drugs Market Attractiveness Analysis, by Disease Type

8. Global Depression Drugs Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Global Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        8.2.1. Hospital Pharmacies

        8.2.2. Retail Pharmacies

        8.2.3. Online Pharmacies

    8.3. Global Depression Drugs Market Attractiveness Analysis, by Distribution Channel

9. Global Depression Drugs Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Depression Drugs Market Value (US$ Mn) Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Global Depression Drugs Market Attractiveness Analysis, by Region

10. North America Depression Drugs Market Analysis and Forecast

    10.1. Introduction

    10.2. North America Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        10.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        10.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        10.2.3. Atypical Antidepressants

        10.2.4. Tricyclic Antidepressants

        10.2.5.  Others 

    10.3. North America Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        10.3.1. Major Depressive Disorder 

        10.3.2. Schizophrenia and Bipolar I Disorder 

        10.3.3. Obsessive-Compulsive Disorders (OCD)

        10.3.4. Anxiety Disorder

        10.3.5. Others

    10.4. North America Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Depression Drugs Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Disease Type

        10.6.3. By Distribution Channel

        10.6.4. By Country 

11. U.S. Depression Drugs Market Analysis and Forecast

    11.1. Introduction

    11.2. U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        11.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        11.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        11.2.3. Atypical Antidepressants

        11.2.4. Tricyclic Antidepressants

        11.2.5.  Others 

    11.3. U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        11.3.1. Major Depressive Disorder 

        11.3.2. Schizophrenia and Bipolar I Disorder 

        11.3.3. Obsessive-Compulsive Disorders (OCD)

        11.3.4. Anxiety Disorder

        11.3.5. Others

    11.4. U.S. Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. U.S. Depression Drugs Market Attractiveness Analysis

        11.5.1. By Drug Class

        11.5.2. By Disease Type

        11.5.3. By Distribution Channel

12. Canada Depression Drugs Market Analysis and Forecast

    12.1. Introduction

    12.2. Canada Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        12.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        12.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        12.2.3. Atypical Antidepressants

        12.2.4. Tricyclic Antidepressants

        12.2.5.  Others 

    12.3. Canada Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        12.3.1. Major Depressive Disorder 

        12.3.2. Schizophrenia and Bipolar I Disorder 

        12.3.3. Obsessive-Compulsive Disorders (OCD)

        12.3.4. Anxiety Disorder

        12.3.5. Others

    12.4. Canada Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Canada Depression Drugs Market Attractiveness Analysis

        12.5.1. By Drug Class

        12.5.2. By Disease Type

        12.5.3. By Distribution Channel

13. Europe Depression Drugs Market Analysis and Forecast

    13.1. Introduction

    13.2. Europe Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        13.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        13.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        13.2.3. Atypical Antidepressants

        13.2.4. Tricyclic Antidepressants

        13.2.5.  Others 

    13.3. Europe Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        13.3.1. Major Depressive Disorder 

        13.3.2. Schizophrenia and Bipolar I Disorder 

        13.3.3. Obsessive-Compulsive Disorders (OCD)

        13.3.4. Anxiety Disorder

        13.3.5. Others

    13.4. Europe Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Europe Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        13.5.1. Germany

        13.5.2. U.K.

        13.5.3. France

        13.5.4. Spain

        13.5.5. Italy

        13.5.6. Rest of Europe

    13.6. Europe Depression Drugs Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Disease Type

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Germany Depression Drugs Market Analysis and Forecast

    14.1. Introduction

    14.2. Germany Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        14.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        14.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        14.2.3. Atypical Antidepressants

        14.2.4. Tricyclic Antidepressants

        14.2.5.  Others 

    14.3. Germany Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        14.3.1. Major Depressive Disorder 

        14.3.2. Schizophrenia and Bipolar I Disorder 

        14.3.3. Obsessive-Compulsive Disorders (OCD)

        14.3.4. Anxiety Disorder

        14.3.5. Others

    14.4. Germany Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Germany Depression Drugs Market Attractiveness Analysis

        14.5.1. By Drug Class

        14.5.2. By Disease Type

        14.5.3. By Distribution Channel

15. France Depression Drugs Market Analysis and Forecast

    15.1. Introduction

    15.2. France Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        15.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        15.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        15.2.3. Atypical Antidepressants

        15.2.4. Tricyclic Antidepressants

        15.2.5.  Others 

    15.3. France Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        15.3.1. Major Depressive Disorder 

        15.3.2. Schizophrenia and Bipolar I Disorder 

        15.3.3. Obsessive-Compulsive Disorders (OCD)

        15.3.4. Anxiety Disorder

        15.3.5. Others

    15.4. France Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        15.4.1. Hospital Pharmacies

        15.4.2. Retail Pharmacies

        15.4.3. Online Pharmacies

    15.5. France Depression Drugs Market Attractiveness Analysis

        15.5.1. By Drug Class

        15.5.2. By Disease Type

        15.5.3. By Distribution Channel

16. U.K. Depression Drugs Market Analysis and Forecast

    16.1. Introduction

    16.2. U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        16.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        16.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        16.2.3. Atypical Antidepressants

        16.2.4. Tricyclic Antidepressants

        16.2.5.  Others 

    16.3. U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        16.3.1. Major Depressive Disorder 

        16.3.2. Schizophrenia and Bipolar I Disorder 

        16.3.3. Obsessive-Compulsive Disorders (OCD)

        16.3.4. Anxiety Disorder

        16.3.5. Others

    16.4. U.K. Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        16.4.1. Hospital Pharmacies

        16.4.2. Retail Pharmacies

        16.4.3. Online Pharmacies

    16.5. U.K. Depression Drugs Market Attractiveness Analysis

        16.5.1. By Drug Class

        16.5.2. By Disease Type

        16.5.3. By Distribution Channel

17. Italy Depression Drugs Market Analysis and Forecast

    17.1. Introduction

    17.2. Italy Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        17.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        17.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        17.2.3. Atypical Antidepressants

        17.2.4. Tricyclic Antidepressants

        17.2.5.  Others 

    17.3. Italy Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        17.3.1. Major Depressive Disorder 

        17.3.2. Schizophrenia and Bipolar I Disorder 

        17.3.3. Obsessive-Compulsive Disorders (OCD)

        17.3.4. Anxiety Disorder

        17.3.5. Others

    17.4. Italy Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        17.4.1. Hospital Pharmacies

        17.4.2. Retail Pharmacies

        17.4.3. Online Pharmacies

    17.5. Italy Depression Drugs Market Attractiveness Analysis

        17.5.1. By Drug Class

        17.5.2. By Disease Type

        17.5.3. By Distribution Channel

18. Spain Depression Drugs Market Analysis and Forecast

    18.1. Introduction

    18.2. Spain Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        18.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        18.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        18.2.3. Atypical Antidepressants

        18.2.4. Tricyclic Antidepressants

        18.2.5.  Others 

    18.3. Spain Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        18.3.1. Major Depressive Disorder 

        18.3.2. Schizophrenia and Bipolar I Disorder 

        18.3.3. Obsessive-Compulsive Disorders (OCD)

        18.3.4. Anxiety Disorder

        18.3.5. Others

    18.4. Spain Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        18.4.1. Hospital Pharmacies

        18.4.2. Retail Pharmacies

        18.4.3. Online Pharmacies

    18.5. Spain Depression Drugs Market Attractiveness Analysis

        18.5.1. By Drug Class

        18.5.2. By Disease Type

        18.5.3. By Distribution Channel

19. Asia Pacific Depression Drugs Market Analysis and Forecast

    19.1. Introduction

    19.2. Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        19.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        19.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        19.2.3. Atypical Antidepressants

        19.2.4. Tricyclic Antidepressants

        19.2.5.  Others 

    19.3. Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        19.3.1. Major Depressive Disorder 

        19.3.2. Schizophrenia and Bipolar I Disorder 

        19.3.3. Obsessive-Compulsive Disorders (OCD)

        19.3.4. Anxiety Disorder

        19.3.5. Others

    19.4. Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        19.4.1. Hospital Pharmacies

        19.4.2. Retail Pharmacies

        19.4.3. Online Pharmacies

    19.5. Asia Pacific Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        19.5.1. China

        19.5.2. Japan

        19.5.3. India

        19.5.4. Australia & New Zealand

        19.5.5. Rest of Asia Pacific

    19.6. Asia Pacific Depression Drugs Market Attractiveness Analysis

        19.6.1. By Drug Class

        19.6.2. By Disease Type

        19.6.3. By Distribution Channel

        19.6.4. By Country/Sub-region

20. Japan Depression Drugs Market Analysis and Forecast

    20.1. Introduction

    20.2. Japan Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        20.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        20.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        20.2.3. Atypical Antidepressants

        20.2.4. Tricyclic Antidepressants

        20.2.5.  Others 

    20.3. Japan Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        20.3.1. Major Depressive Disorder 

        20.3.2. Schizophrenia and Bipolar I Disorder 

        20.3.3. Obsessive-Compulsive Disorders (OCD)

        20.3.4. Anxiety Disorder

        20.3.5. Others

    20.4. Japan Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        20.4.1. Hospital Pharmacies

        20.4.2. Retail Pharmacies

        20.4.3. Online Pharmacies

    20.5. Japan Depression Drugs Market Attractiveness Analysis

        20.5.1. By Drug Class

        20.5.2. By Disease Type

        20.5.3. By Distribution Channel

21. China Depression Drugs Market Analysis and Forecast

    21.1. Introduction

    21.2. China Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        21.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        21.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        21.2.3. Atypical Antidepressants

        21.2.4. Tricyclic Antidepressants

        21.2.5.  Others 

    21.3. China Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        21.3.1. Major Depressive Disorder 

        21.3.2. Schizophrenia and Bipolar I Disorder 

        21.3.3. Obsessive-Compulsive Disorders (OCD)

        21.3.4. Anxiety Disorder

        21.3.5. Others

    21.4. China Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        21.4.1. Hospital Pharmacies

        21.4.2. Retail Pharmacies

        21.4.3. Online Pharmacies

    21.5. China Depression Drugs Market Attractiveness Analysis

        21.5.1. By Drug Class

        21.5.2. By Disease Type

        21.5.3. By Distribution Channel

22. India Depression Drugs Market Analysis and Forecast

    22.1. Introduction

    22.2. India Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        22.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        22.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        22.2.3. Atypical Antidepressants

        22.2.4. Tricyclic Antidepressants

        22.2.5.  Others 

    22.3. India Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        22.3.1. Major Depressive Disorder 

        22.3.2. Schizophrenia and Bipolar I Disorder 

        22.3.3. Obsessive-Compulsive Disorders (OCD)

        22.3.4. Anxiety Disorder

        22.3.5. Others

    22.4. India Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        22.4.1. Hospital Pharmacies

        22.4.2. Retail Pharmacies

        22.4.3. Online Pharmacies

    22.5. India Depression Drugs Market Attractiveness Analysis

        22.5.1. By Drug Class

        22.5.2. By Disease Type

        22.5.3. By Distribution Channel

23. Australia & New Zealand Depression Drugs Market Analysis and Forecast

    23.1. Introduction

    23.2. Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        23.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        23.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        23.2.3. Atypical Antidepressants

        23.2.4. Tricyclic Antidepressants

        23.2.5.  Others 

    23.3. Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        23.3.1. Major Depressive Disorder 

        23.3.2. Schizophrenia and Bipolar I Disorder 

        23.3.3. Obsessive-Compulsive Disorders (OCD)

        23.3.4. Anxiety Disorder

        23.3.5. Others

    23.4. Australia & New Zealand Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        23.4.1. Hospital Pharmacies

        23.4.2. Retail Pharmacies

        23.4.3. Online Pharmacies

    23.5. Australia & New Zealand Depression Drugs Market Attractiveness Analysis

        23.5.1. By Drug Class

        23.5.2. By Disease Type

        23.5.3. By Distribution Channel

24. Latin America Depression Drugs Market Analysis and Forecast

    24.1. Introduction

    24.2. Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        24.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        24.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        24.2.3. Atypical Antidepressants

        24.2.4. Tricyclic Antidepressants

        24.2.5.  Others 

    24.3. Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        24.3.1. Major Depressive Disorder 

        24.3.2. Schizophrenia and Bipolar I Disorder 

        24.3.3. Obsessive-Compulsive Disorders (OCD)

        24.3.4. Anxiety Disorder

        24.3.5. Others

    24.4. Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        24.4.1. Hospital Pharmacies

        24.4.2. Retail Pharmacies

        24.4.3. Online Pharmacies

    24.5. Latin America Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        24.5.1. Brazil

        24.5.2. Mexico

        24.5.3. Rest of Latin America

    24.6. Latin America Depression Drugs Market Attractiveness Analysis

        24.6.1. By Drug Class

        24.6.2. By Disease Type

        24.6.3. By Distribution Channel

        24.6.4. By Country/Sub-region

25. Brazil Depression Drugs Market Analysis and Forecast

    25.1. Introduction

    25.2. Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        25.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        25.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        25.2.3. Atypical Antidepressants

        25.2.4. Tricyclic Antidepressants

        25.2.5.  Others 

    25.3. Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        25.3.1. Major Depressive Disorder 

        25.3.2. Schizophrenia and Bipolar I Disorder 

        25.3.3. Obsessive-Compulsive Disorders (OCD)

        25.3.4. Anxiety Disorder

        25.3.5. Others

    25.4. Brazil Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        25.4.1. Hospital Pharmacies

        25.4.2. Retail Pharmacies

        25.4.3. Online Pharmacies

    25.5. Brazil Depression Drugs Market Attractiveness Analysis

        25.5.1. By Drug Class

        25.5.2. By Disease Type

        25.5.3. By Distribution Channel

26. Mexico Depression Drugs Market Analysis and Forecast

    26.1. Introduction

    26.2. Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        26.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        26.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        26.2.3. Atypical Antidepressants

        26.2.4. Tricyclic Antidepressants

        26.2.5.  Others 

    26.3. Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        26.3.1. Major Depressive Disorder 

        26.3.2. Schizophrenia and Bipolar I Disorder 

        26.3.3. Obsessive-Compulsive Disorders (OCD)

        26.3.4. Anxiety Disorder

        26.3.5. Others

    26.4. Mexico Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        26.4.1. Hospital Pharmacies

        26.4.2. Retail Pharmacies

        26.4.3. Online Pharmacies

    26.5. Mexico Depression Drugs Market Attractiveness Analysis

        26.5.1. By Drug Class

        26.5.2. By Disease Type

        26.5.3. By Distribution Channel

27. Middle East & Africa Depression Drugs Market Analysis and Forecast

    27.1. Introduction

    27.2. Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        27.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        27.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        27.2.3. Atypical Antidepressants

        27.2.4. Tricyclic Antidepressants

        27.2.5.  Others 

    27.3. Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        27.3.1. Major Depressive Disorder 

        27.3.2. Schizophrenia and Bipolar I Disorder 

        27.3.3. Obsessive-Compulsive Disorders (OCD)

        27.3.4. Anxiety Disorder

        27.3.5. Others

    27.4. Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        27.4.1. Hospital Pharmacies

        27.4.2. Retail Pharmacies

        27.4.3. Online Pharmacies

    27.5. Middle East & Africa Depression Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        27.5.1. GCC Countries

        27.5.2. South Africa

        27.5.3. Rest of Middle East & Africa

    27.6. Middle East & Africa Depression Drugs Market Attractiveness Analysis

        27.6.1. By Drug Class

        27.6.2. By Disease Type

        27.6.3. By Distribution Channel

        27.6.4. By Country/Sub-region

28. GCC Countries Depression Drugs Market Analysis and Forecast

    28.1. Introduction

    28.2. GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        28.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        28.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        28.2.3. Atypical Antidepressants

        28.2.4. Tricyclic Antidepressants

        28.2.5.  Others 

    28.3. GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        28.3.1. Major Depressive Disorder 

        28.3.2. Schizophrenia and Bipolar I Disorder 

        28.3.3. Obsessive-Compulsive Disorders (OCD)

        28.3.4. Anxiety Disorder

        28.3.5. Others

    28.4. GCC Countries Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        28.4.1. Hospital Pharmacies

        28.4.2. Retail Pharmacies

        28.4.3. Online Pharmacies

    28.5. GCC Countries Depression Drugs Market Attractiveness Analysis

        28.5.1. By Drug Class

        28.5.2. By Disease Type

        28.5.3. By Distribution Channel

29. South Africa Depression Drugs Market Analysis and Forecast

    29.1. Introduction

    29.2. South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        29.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs) 

        29.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) 

        29.2.3. Atypical Antidepressants

        29.2.4. Tricyclic Antidepressants

        29.2.5.  Others 

    29.3. South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

        29.3.1. Major Depressive Disorder 

        29.3.2. Schizophrenia and Bipolar I Disorder 

        29.3.3. Obsessive-Compulsive Disorders (OCD)

        29.3.4. Anxiety Disorder

        29.3.5. Others

    29.4. South Africa Depression Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        29.4.1. Hospital Pharmacies

        29.4.2. Retail Pharmacies

        29.4.3. Online Pharmacies

    29.5. South Africa Depression Drugs Market Attractiveness Analysis

        29.5.1. By Drug Class

        29.5.2. By Disease Type

        29.5.3. By Distribution Channel

30. Competition Landscape

    30.1. Competition Matrix

    30.2. Market Share Analysis, by Company, 2019

    30.3. Company Profiles

        30.3.1. Novartis AG 

            30.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            30.3.1.2. Company Financials

            30.3.1.3. Growth Strategies

            30.3.1.4. SWOT Analysis

        30.3.2. GlaxoSmithKline plc 

            30.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            30.3.2.2. Company Financials

            30.3.2.3. Growth Strategies

            30.3.2.4. SWOT Analysis

        30.3.3. Eli Lilly and Company 

            30.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            30.3.3.2. Company Financials

            30.3.3.3. Growth Strategies

            30.3.3.4. SWOT Analysis

        30.3.4. Pfizer, Inc. 

            30.3.4.1. Company Overview (HQ, Business Segments)

            30.3.4.2. Company Financials

            30.3.4.3. Growth Strategies

            30.3.4.4. SWOT Analysis

        30.3.5. Allergan plc

            30.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            30.3.5.2. Company Financials

            30.3.5.3. Growth Strategies

            30.3.5.4. SWOT Analysis

        30.3.6. Takeda Pharmaceutical Company Limited

            30.3.6.1. Company Overview (HQ, Business Segments)

            30.3.6.2. Company Financials

            30.3.6.3. Growth Strategies

            30.3.6.4. SWOT Analysis

        30.3.7. AstraZeneca plc 

            30.3.7.1. Company Overview (HQ, Business Segments)

            30.3.7.2. Company Financials

            30.3.7.3. Growth Strategies

            30.3.7.4. SWOT Analysis

        30.3.8. Johnson & Johnson 

            30.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            30.3.8.2. Company Financials

            30.3.8.3. Growth Strategies

            30.3.8.4. SWOT Analysis

        30.3.9. Abbott 

            30.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            30.3.9.2. Company Financials

            30.3.9.3. Growth Strategies

            30.3.9.4. SWOT Analysis

        30.3.10. Otsuka Pharmaceutical Co., Ltd. 

            30.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            30.3.10.2. Company Financials

            30.3.10.3. Growth Strategies

            30.3.10.4. SWOT Analysis